Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.68 -1.14 (-6.08%)
Streaming Delayed Price Updated: 12:26 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,670,681
Open 17.47
Bid (Size) 17.68 (3)
Ask (Size) 17.69 (10)
Prev. Close 18.83
Today's Range 16.31 - 18.11
52wk Range 15.55 - 36.91
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top 3 Health Care Stocks You'll Regret Missing In Q3
 
Via Benzinga
Is Summit Therapeutics a Buy, Sell, or Hold Now?
Western results for ivonescimab aren't lining up with the huge survival benefit measured in China. 
Via The Motley Fool

Performance

YTD
-3.6%
-3.6%
1 Month
-37.4%
-37.4%
3 Month
-19.9%
-19.9%
6 Month
-4.4%
-4.4%
1 Year
-7.6%
-7.6%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Gold Moves Higher; Robinhood Shares Jump
Via Benzinga
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Via Investor's Business Daily
Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains
Via Stocktwits
Top movers in Monday's pre-market session
Via Chartmill
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Via Benzinga
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
From Summit Therapeutics
Via Business Wire
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3
Via Stocktwits
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
From Summit Therapeutics
Via Business Wire
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio?
Via Benzinga
3 No-Brainer Stocks to Buy Right Now
Via The Motley Fool
Topics World Trade
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Via Benzinga
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
JM Smucker, Baidu And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside
Via Stocktwits
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Fantastic Growth Stocks to Buy in August
Via The Motley Fool
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
From Summit Therapeutics
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
From Summit Therapeutics
Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 17.68
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 09/10/25 12:26 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.72B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.